Phosphatidylinositol 3-kinase regulatory subunit alpha (PIK3R1) (PIK3R1)

Phosphatidylinositol 3-kinase regulatory subunit alpha (PIK3R1), commonly known as p85alpha, is a critical regulatory component of the Class IA phosphatidylinositol 3-kinase (PI3K) complex [1, 11]. In its basal state, p85alpha binds to and inhibits the p110 catalytic subunit, while also providing structural stability to the enzyme [2, 12]. Upon activation of receptor tyrosine kinases (RTKs) by growth factors or insulin, p85alpha uses its SH2 domains to recruit the PI3K complex to the plasma membrane, relieving its inhibitory hold on p110 and initiating the conversion of PIP2 to PIP3 [11, 19]. This molecular switch is fundamental for intracellular signaling cascades that govern cell growth, survival, and metabolic functions like glucose uptake [1, 2, 4].\n\nDysregulation of PIK3R1 is a hallmark of numerous human pathologies. Somatic gain-of-function mutations in PIK3R1 are frequent drivers in endometrial, breast, and ovarian cancers, where they lead to constitutive activation of the oncogenic PI3K/AKT/mTOR pathway [2, 3, 15]. Conversely, germline loss-of-function mutations cause SHORT syndrome and metabolic disorders like insulin resistance, while other specific variants result in Activated PI3K-delta syndrome type 2 (APDS2) [4, 5, 7]. Although most clinical PI3K inhibitors, such as Alpelisib and Copanlisib, target the p110 catalytic subunit, the regulatory p85alpha subunit is essential for the complex's function, and its mutation status often serves as a predictive biomarker for therapeutic response [10, 12, 16].

Other names

p85alphap85-alphap85GRB1AGM7IMD36Phosphatidylinositol 3-kinase 85 kDa regulatory subunit alphaPI3-kinase subunit p85-alpha

Drugs typically target the ATP-binding pocket of the p110 catalytic subunit within the PI3K complex (stabilized by p85alpha) to inhibit the conversion of PIP2 to PIP3, thereby blocking downstream signaling via the AKT/mTOR pathway [11, 19]. Some agents like AKT inhibitors are used to target tumors where p85alpha loss or mutation drives constitutive pathway activation [16].